RxSight, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 40 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-09-15: Reporting owner Weinberg Eric; Form 4; Security Stock Option (right to buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-09-05: Reporting owner Wilterding Mark; Form 4; Security Stock Option (right to buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
- 2026-09-05: Reporting owner Wilterding Mark; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-09-05: Reporting owner Weinberg Eric; Form 4; Security Stock option (right to buy); Transaction D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e).
RXST insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-09-15 | Weinberg Eric Officer (See remarks) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −35,168 0 owned after | $4.34 exercise price | $5.62 | 2026-09-16 |
| 2026-09-05 | Wilterding Mark Officer (Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −258,770 0 owned after | $10.09 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Wilterding Mark Officer (Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +258,770 258,770 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Weinberg Eric Officer (See remarks) | 4 | Stock option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −87,437 0 owned after | $16.00 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Weinberg Eric Officer (See remarks) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −95,000 0 owned after | $14.95 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Weinberg Eric Officer (See remarks) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −92,200 0 owned after | $56.07 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Weinberg Eric Officer (See remarks) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $46.24 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Weinberg Eric Officer (See remarks) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −125,000 0 owned after | $28.21 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Weinberg Eric Officer (See remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +65,742 65,742 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Weinberg Eric Officer (See remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,608 82,608 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Weinberg Eric Officer (See remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +59,483 59,483 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Weinberg Eric Officer (See remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,258 32,258 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Weinberg Eric Officer (See remarks) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +93,984 93,984 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Kurtz Ronald M MD Officer (Chief Medical Officer) | 4 | Stock option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −338,819 0 owned after | $16.00 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Kurtz Ronald M MD Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −200,000 0 owned after | $14.95 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Kurtz Ronald M MD Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −149,000 0 owned after | $56.07 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Kurtz Ronald M MD Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −215,000 0 owned after | $28.21 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Kurtz Ronald M MD Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +254,751 254,751 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Kurtz Ronald M MD Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +173,913 173,913 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Kurtz Ronald M MD Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +96,129 96,129 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Kurtz Ronald M MD Officer (Chief Medical Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +161,654 161,654 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −98,367 0 owned after | $16.00 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −120,000 0 owned after | $14.95 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −92,200 0 owned after | $56.07 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −50,000 0 owned after | $46.24 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) | −125,000 0 owned after | $28.21 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +73,960 73,960 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +104,347 104,347 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +59,483 59,483 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +32,258 32,258 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-09-05 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +93,984 93,984 owned after | $6.38 exercise price | $6.38 | 2026-09-09 |
| 2026-07-24 | Mottiwala Aziz Director, Officer (President and CEO) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +571,286 571,286 owned after | $5.19 exercise price | $5.19 | 2026-07-24 |
| 2026-04-17 | Goldshleger Ilya Officer (Chief Operating Officer) | 4 | Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,489 5 owned after | $4.13 exercise price | $7.61 | 2026-04-20 |
| 2026-01-15 holding as of filing | Gaines Scott Officer (Chief Customer Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $12.85 exercise price | 2026-01-15 | ||
| 2026-01-15 holding as of filing | Gaines Scott Officer (Chief Customer Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $14.95 exercise price | 2026-01-15 | ||
| 2026-01-15 holding as of filing | Gaines Scott Officer (Chief Customer Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $56.07 exercise price | 2026-01-15 | ||
| 2026-01-15 holding as of filing | Gaines Scott Officer (Chief Customer Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $46.24 exercise price | 2026-01-15 | ||
| 2026-01-15 holding as of filing | Gaines Scott Officer (Chief Customer Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $28.21 exercise price | 2026-01-15 | ||
| 2026-01-15 holding as of filing | Gaines Scott Officer (Chief Customer Officer) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $7.78 exercise price | 2026-01-15 | ||
| 2026-01-12 | Wilterding Mark Officer (Chief Financial Officer) | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +258,770 258,770 owned after | $10.09 exercise price | $10.09 | 2026-01-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |